DSP Healthcare Fund - Regular Plan - Growth
Category: Equity: Sectoral-Pharma and Healthcare
Launch Date: 05-11-2018
AUM:
3,628.03 Cr
Expense Ratio
2.02%
Benchmark
BSE Healthcare TRI
ISIN
INF740KA1LD8
Minimum Investment
100.0
Minimum Topup
100.0
Minimum SIP Amount
100
Fund Manager
Chirag Dagli
| Fund Performance | 1Y (%) | 3Y (%) | 5Y (%) |
|---|---|---|---|
| DSP Healthcare Fund - Regular Plan - Growth | 14.57 | 20.59 | 15.0 |
| Benchmark | - | - | - |
If you invested in this fund:
₹
In the past (time duration):
Total value today:
0
Returns:
0%
If you invested in this fund:
In the past (time duration):
Total value today:
0
Returns:
0%
Overview
NAV
45.519
Last change
-0.09 (-0.2021%)
Fund Size (AUM)
₹ 3,628.03 Cr
Performance
21.67% (Inception)
Asset Allocation
Equity
Debt
Others
Nav Movement
Investment Objective
The primary investment objective of the scheme is to seek to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies. There is no assurance that the investment objective of the Scheme will be achieved
Fund Manager
Chirag Dagli
Riskometer
Very High
Top 10 Holdings
| Company | Holdings (%) |
|---|---|
| CIPLA LIMITED EQ NEW FV RS.2/- | 8.35 |
| IPCA LABORATORIES LIMITED EQ NEW FV RE .1/- | 8.21 |
| SUN PHARMACEUTICAL INDUSTRIES LTD. EQ NEW F.V. RE.1/- | 8.14 |
| TREPS / Reverse Repo Investments | 7.64 |
| ILLUMINA INC | 7.59 |
| Sai Life Sciences Limited | 6.88 |
| GLAND PHARMA LIMITED EQ NEW FV Re.1/- | 6.54 |
| Globus Medical Inc | 5.72 |
| APOLLO HOSPITALS ENTERPRISE LIMITED EQ NEW F.V. RS.5/- | 4.81 |
| SUVEN PHARMACEUTICALS LIMITED EQ | 4.13 |
Sector Allocation
| Sector | Holdings (%) |
|---|---|
| Healthcare | 74.85 |
| Financial Services | 1.2 |